United States Food and Drug Administration (USFDA) has concluded Good Manufacturing Practice (GMP) inspection at Gland Pharma’s VSEZ Sterile Oncology facility at Visakhapatnam. The said inspection has conducted between July 20, 2023 and July 28, 2023. The inspection was concluded with (Zero) 483 observations and a classification of No Action Indicated (NAI).
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.
